Biotechnology

CAR-T Conference
Health

How to pay for CAR-T: A conversation with health policy expert Peter Bach

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Minds
Biotech

A scrappy crew of biotechs is working on a new wave of schizophrenia medicines

By Meghana Keshavan

The Readout LOUD

LISTEN: A lesson in startup jargon, pharma’s bare Alzheimer’s cupboard, and the cost of CAR-T

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

China biotech flag
Biotech

The Nasdaq’s newest ETF invites investors to bet on Chinese biopharma

By Rebecca Robbins

STAT SPOTLIGHT
Biotech

Startup Spotlight: Flagship Pioneering’s Sigilon gets a new CEO

By Kate Sheridan

Alnylam RNAi
Biotech

A landmark drug approval shows RNAi’s promise — even as it hints at its limits

By Kate Sheridan

John and Megan Crowley
Biotech

Amicus’ rare disease drug, once indefinitely delayed, wins FDA approval

By Damian Garde

Alnylam headquarters
Biotech

FDA approves first-ever RNAi-based therapy

By Kate Sheridan

The Readout LOUD

LISTEN: Insider trading goes to Washington, online bloodshed over fake meat, & doctors vs. fund managers

By Damian Garde and Rebecca Robbins

Dr. Steven Rosenberg
In the Lab

After 30 years, an immunotherapy to rival CAR-T finally nears the clinic

By Sharon Begley

Vertex
Business

Vertex gets approval to treat toddlers with cystic fibrosis drug

By Jonathan Saltzman — Boston Globe

MORE Red Blood Cells
Biotech

Wall Street is writing off Spark’s hemophilia gene therapy. Clinicians are not

By Damian Garde

Red Blood Cells
Biotech

Spark’s gene therapy data answer some burning questions — and raise a few more

By Damian Garde

Biotech

The FDA is poised to approve the first-ever drug that mutes disease-causing genes

By Kate Sheridan

Business

Investors are pouring more money into biotech funds, and stocks are responding

By Adam Feuerstein

The Readout LOUD

LISTEN: Biotech’s sellers market, Sanofi’s second act, and literally climbing Mt. Everest

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Adam's Take

Geron’s prodigious fundraising activity signals low confidence in J&J relationship

By Adam Feuerstein

A microscope image of frozen baker's yeast.
In the Lab

Assembling yeast chromosomes like Legos has a serious goal: safe lab-made creatures

By Sharon Begley

A woman looking into a microscope.
First Opinion

Gender inequality still plagues the health care industry. Women are fed up

By Halle Tecco

Paula Soteropoulos, CEO of Akcea Therapeutics.
Biotech

Two Akcea drugs are about to hit the market — but are they already too late?

By Kate Sheridan

Gene Therapy Recruiters
Biotech

Stock, sky-high salaries and a $10,000 watch: Startups desperately compete for top experts in gene and cell therapy

By Rebecca Robbins

A dosage of Spinraza.
Biotech

For UMass Medical School, Spinraza sales add millions to the budget

By Kate Sheridan

Hepatitis Drugs
Adam's Take

Gilead Sciences’ board is looking for a new CEO. Here’s a list of possible contenders

By Adam Feuerstein

The Readout LOUD

LISTEN: A debatable Alzheimer’s breakthrough, Gilead’s golden age, and separating smart money from dumb

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

Biotech

Here’s why Biogen lost $7 billion overnight despite ‘positive’ Alzheimer’s data

By Damian Garde

Sarepta
Biotech

Sarepta halts early-stage gene therapy trial for DMD

By Kate Sheridan

Adam's Take

Gilead’s golden era ends with the executive departures of ‘The Johns’

By Adam Feuerstein

Biotech

Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment

By Damian Garde

Pregnant Gene Therapy
In the Lab

Can gene therapy halt diseases in babies before they’re even born?

By Andrew Joseph

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy